Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Solid Tumors

NCT05907980 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT05907980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05907980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 1
Overall status
Recruiting
Start date
May 24, 2023
Completion date
October 31, 2027
Enrollment
209 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor